MWMargaret E. Wright

Margaret E. Wright

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margaret E. Wright has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Anne M. Hartman

    Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

    1 shared publication
  • Brenda K. Edwards

    Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

    1 shared publication
  • Demetrius Albanes

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

    1 shared publication
  • Jarmo Virtamo

    Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

    1 shared publication
  • Jussi K. Huttunen

    Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

    1 shared publication
  • Philip R. Taylor

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

    1 shared publication

Latest Publications

  • Effects of α‐tocopherol and β‐carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial

    by Margaret E. Wright, Jarmo Virtamo, Anne M. Hartman, Pirjo Pietinen, Brenda K. Edwards, Philip R. Taylor, Jussi K. Huttunen, Demetrius Albanes

    BACKGROUND.: Although smoking and alcohol consumption are the major risk factors for upper aerodigestive tract cancers, observational studies indicate a protective role for fruits, vegetables, and antioxidant nutrients.METHODS.: The authors examined whether daily supplementation with 50 mg dl α‐tocopheryl acetate and/or 20 mg β‐carotene reduced the incidence of or mortality from oral/pharyngeal, esophageal, and laryngeal cancers in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) study, a double‐blind, placebo‐controlled primary prevention trial conducted in southwestern Finland. A total of 29,133 male smokers, aged 50–69 years and free of cancer at baseline, were randomized in a 2 × 2 factorial design to the supplementation regimen for 5–8 years (median, 6.1 years). Incident cancers of the oral cavity and pharynx (n = 65), esophagus (n = 24), and larynx (n = 56) were identified through the Finnish Cancer Registry. Intervention effects were assessed using survival analysis and proportional hazards models.RESULTS.: There was no effect of either agent on the overall incidence of any upper aerodigestive tract cancer. For larynx, however, exploratory subgroup analyses were suggestive of a protective effect of β‐carotene supplementation on the incidence of early stage malignancies (stage I, relative risk [RR], 0.28, 95% confidence interval [CI]: 0.10–0.75). Neither agent affected mortality from these neoplasms.CONCLUSIONS.: The results do not provide support for a protective effect of vitamin E or β‐carotene supplementation on upper aerodigestive tract cancers, although β‐carotene supplementation may impact the incidence of some subtypes of laryngeal tumors. Cancer 2007 © 2007 American Cancer Society.